v3.26.1
Collaborative Arrangements (Tables)
 6 Months Ended
Jun. 30, 2026
Collaborative Arrangements [Abstract]  
Schedule of Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2026202520262025
Alliance revenue - Lynparza$365 $370 $706 $682 
Alliance revenue - Koselugo (1)
10 43 171 87 
Total alliance revenue$375 $413 $877 $769 
Cost of sales (2)
84 86 169 169 
Selling, general and administrative25 40 49 72 
Research and development9 16 15 28 
($ in millions)June 30, 2026December 31, 2025
Receivables from AstraZeneca included in Other current assets (3)
$375 $451 
Receivables from AstraZeneca included in Other assets (3)
125 125 
Payables to AstraZeneca included in Accrued and other current liabilities
6 6 
(1)    Amount in the first six months of 2026 includes $150 million related to the amendment of the collaboration agreement noted above.
(2)    Represents amortization of capitalized milestone payments.
(3)    Includes milestone receivables.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2026202520262025
Alliance revenue - Lenvima$283 $265 $539 $523 
Cost of sales (1)
13 60 26 121 
Selling, general and administrative29 35 56 66 
Research and development— 3 2 7 
($ in millions)June 30, 2026December 31, 2025
Receivables from Eisai included in Other current assets
$281 $271 
(1)    Represents amortization of capitalized milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2026202520262025
Alliance revenue - Adempas/Verquvo$126 $123 $235 $229 
Net sales of Adempas recorded by Merck78 80 156 147 
Net sales of Verquvo recorded by Merck9 11 18 21 
Total sales$213 $214 $409 $397 
Cost of sales (1)
67 61 134 120 
Selling, general and administrative11 29 23 58 
Research and development10 20 27 43 
($ in millions)June 30, 2026December 31, 2025
Receivables from Bayer included in Other current assets
$166 $167 
Payables to Bayer included in Accrued and other current liabilities
86 81 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2026202520262025
Net sales of Lagevrio recorded by Merck
$5 $83 $32 $185 
Cost of sales (1)
14 44 67 97 
Selling, general and administrative
9 14 19 28 
Research and development
5 6 10 14 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2026202520262025
Selling, general and administrative $12 $4 $24 $13 
Research and development
181 193 341 321 
($ in millions)June 30, 2026December 31, 2025
Receivables from Daiichi Sankyo included in Other current assets
$27 $15 
Payables to Daiichi Sankyo included in Accrued and other current liabilities
100 113 
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2026202520262025
Selling, general and administrative $9 $6 $17 $12 
Research and development (1)
94 90 184 176 
($ in millions)June 30, 2026December 31, 2025
Receivables from Moderna included in Other current assets
$15 $— 
Payables to Moderna included in Accrued and other current liabilities
— 13 
(1)    Includes amortization of shared facility costs.